FARMINGDALE, N.Y., July 18, 2016 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, hosted a successful BoneScalpel Hands-On Workshop during the International Meeting on Advanced Spine Technologies ("IMAST") in Washington, DC last week. More than 30 surgeons attended the workshop and were trained on advanced spine surgical techniques utilizing the BoneScalpel.
This year's Ultrasonics in Spine Surgery: BoneScalpel Hands-On Workshop was co-moderated by Dr. Amer Samdani, Shriners Hospital for Children, Philadelphia, PA, and Dr. Suken Shah, Nemours/Alfred I. DuPont Hospital for Children, Wilmington, DE.
The faculty presented their clinical experience with the BoneScalpel focusing on the safer, more efficient surgical experience with repeatable reduction in blood loss and an increase in the amount of viable autogenous bone graft harvested.
Dr. Suken Shah commented, "The BoneScalpel has become an important instrument in my surgical practice as it has enabled procedures that are faster with considerably less blood loss as compared to those done with conventional surgical instruments. It's encouraging to see so many new surgeons coming to events like this workshop looking to learn how to incorporate it into their own practices."
Dr. Amer Samdani added, "I've now been using BoneScalpel for a number of years and find that it's a fantastic instrument offering a number of benefits. Events like this year's workshop are important for new surgeons to gain confidence with the technology and understand how it can add value and safety to their procedures."
Scott Ludecker, Senior Vice President of Global Sales and Marketing for Misonix, added, "More and more surgeons are seeking opportunities to learn how to incorporate BoneScalpel into their own practices around the globe. Events like the workshop at IMAST this year are important forums for these new surgeons to learn from leading experts that have already integrated the BoneScalpel into their own operating rooms and can share their experience."
"Misonix has hosted BoneScalpel Hands-On Workshops for the past several years at IMAST and other conferences around the world with large registration numbers and this year was another well attended event. The events are particularly successful because of the well-recognized surgeons who are the instructors. Doctors experience not only the use of the BoneScalpel but benefit from the instruction and actual experience of prominent surgeons. Hearing the benefits of the BoneScalpel in cutting bone, in the reduction in blood loss, safety and other benefits from their respected colleagues is impressive to all. Our commitment to medical education and for training surgeons on advanced surgical techniques with our advanced technology is central to our mission at Misonix," added Michael A. McManus, Jr., President and CEO of Misonix.
About Misonix Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.